Drug Res (Stuttg) 2018; 68(09): 499-503
DOI: 10.1055/s-0043-119069
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Antimicrobial Peptidomimetics for Recurrent Septicemia Infections: In Vitro Study for Immuno Compromised Disease Target

Priyanka Sharma
1   P.G Research Scholar, Department of Pharmacology, KIET School of Pharmacy, Ghaziabad, Delhi-NCR, India
,
Kandasamy Nagarajan
2   Professor & Head, Department of Pharmaceutical Chemistry, KIET School of Pharmacy, Ghaziabad, Delhi-NCR, India
,
Bihu Prasad Panda
3   Microbial and pharmaceutical biotechnology laboratory. Hamdarad University, New Delhi, India
› Author Affiliations
Further Information

Publication History

received 10 April 2017

accepted 20 July 2017

Publication Date:
16 April 2018 (online)

Preview

Abstract

The frequency of Bacillus subtilis infection such as pneumonia pan-opthalmitis, visceral abscess or musculoskeletal infection etc. complications following bacteremia, meningitis in children & the infection associated with majority of motor vehicle accidents associated with trauma & gun shoot injury. Antibiotics which appear especially useful in the treatment of Bacillus. infection are clindamycin and vancomycin to which vast majority of strains are susceptible in vitro. Our objective is to test the synthesized peptidomimetics with the efforts mainly directed towards the identification of antibacterial compounds against recurrent septicemia infection. Six peptidomimetics namely G-A-L-D (C60-soot Glu-ala-leu-Asp), D-P-F (C60-soot Asp-pro-Phe), I-R (C60-soot Ile-Arg), L-R (C60-soot leu-Arg), E-R (C60-soot Glu-Arg), D-E (C60-soot Asp-Glu), the column eluted compounds were tested for disc diffusion using gram positive Bacillus Subtilis strains at different concentrations predicted by pH and inhibitory concentrations. I-R (C60-soot Ile-Arg), & D-E (C60-soot Asp-Glu) was found to be very effective along with 5 compounds against Bacillus Subtilis strain tested. Maximum activity 100 µg/ml for synthesized peptidomimetics with the corresponding zonal inhibition diameter (11 mm; 11 mm; 14 mm; 11 mm; 11 mm; 14 mm) against Bacillus subtilis strain. This is the first evidence based report that proves I-R (C60-soot Ile-Arg) & D-E (C60-soot Asp-Glu) has shown antibacterial action against gram positive strains of Bacillus Subtilis against recurrent septicemia infection